News From the Food and Drug Administration.

Citation metadata

Date: Jan. 19, 2021
Publisher: American Medical Association
Document Type: Article
Length: 58 words

Document controls

Main content

Abstract :

The FDA approved lumasiran (Oxlumo) as the first treatment for primary hyperoxaluria type 1. Approval was granted to gallium 68 prostate-specific membrane antigen 11, a radioactive tracer for use with positron emission tomographic imaging to treat patients with prostate cancer. The FDA cautioned that face masks contain metal that could cause injury during a magnetic resonance imaging examination.

Source Citation

Source Citation   

Gale Document Number: GALE|A653145712